Fidelity Global Technology vs UBS Lux Equity Fund Biotech USD

Fidelity Global Technology vs UBS Lux Equity Fund Biotech USD

1. Fidelity Global Technology

  • Security

    Fidelity Global Technology A Dist EUR

  • Fee

    1.89%

  • ISIN

    LU0099574567

  • Holdings

    21

2. UBS Lux Equity Fund Biotech USD

  • Security

    UBS Lux Equity Fund Biotech USD P-acc

  • Fee

    2.25%

  • ISIN

    LU0069152568

  • Holdings

    9

Fund Holdings

We have information about 30 holdings in Fidelity Global Technology, where the largest holding is TSMC (7.53), followed by Microsoft (6.05) and Apple (4.55). In comparison with UBS Lux Equity Fund Biotech USD, we have 11 holdings where Regeneron Pharmaceuticals is the largest holding (10.04), followed by Moderna (9.21) and Vertex (8.44).

All Holdings

Here we compare the holdings in Fidelity Global Technology and UBS Lux Equity Fund Biotech USD.

Fidelity Global Technology UBS Lux Equity Fund Biotech USD
1. Taiwan Semiconductor Manufacturing Company
Taiwan
7.53 %
1. Regeneron Pharmaceuticals Inc
10.04 %
2. Microsoft Corp
USA
6.05 %
2. Moderna Inc
9.21 %
3. Apple Inc
USA
4.55 %
3. Vertex Pharmaceuticals Inc
8.44 %
4. Alphabet Inc Class A
USA
4.5 %
4. Alnylam Pharmaceuticals Inc
8.08 %
5. Amazon.com Inc
USA
3.11 %
5. AbbVie Inc
USA
4.91 %
6. Ericsson B
Sweden
2.97 %
6. Gilead Sciences Inc
USA
4.66 %
7. Texas Instruments Inc
USA
2.63 %
7. Amgen Inc
USA
4.43 %
8. Cisco Systems Inc
USA
1.96 %
8. BioNTech SE
4.13 %
9. Meta Platforms A
USA
1.92 %
9. Karuna Therapeutics Inc
3.75 %
10. Western Digital Technologies Inc
USA
1.84 %
-
11. Workday A
USA
1.78 %
-
12. Adobe Inc
USA
1.77 %
-
13. Microchip Technology Inc
USA
1.77 %
-
14. Ansys Inc
1.55 %
-
15. Autodesk Inc
1.47 %
-
16. Marvell Technology Inc
USA
1.45 %
-
17. Accenture Plc
Ireland
1.36 %
-
18. BE Semiconductor Industries NV
Netherlands
1.31 %
-
19. Lam Research Corp
USA
1.27 %
-
20. Intel Corp
USA
1.25 %
-
21. Samsung Electronics Co Ltd
South Korea
1.17 %
-

The list of fund holdings was last updated on July 25, 2025.